CA2289564A1 - Preparation of glycosylated tumor necrosis factor - Google Patents

Preparation of glycosylated tumor necrosis factor Download PDF

Info

Publication number
CA2289564A1
CA2289564A1 CA002289564A CA2289564A CA2289564A1 CA 2289564 A1 CA2289564 A1 CA 2289564A1 CA 002289564 A CA002289564 A CA 002289564A CA 2289564 A CA2289564 A CA 2289564A CA 2289564 A1 CA2289564 A1 CA 2289564A1
Authority
CA
Canada
Prior art keywords
tnf
glycosylated
necrosis factor
tumor necrosis
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002289564A
Other languages
English (en)
French (fr)
Inventor
Ziva Messika
Adrian Harel
Menachem Ze'evi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Interpharm Laboratories Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2289564A1 publication Critical patent/CA2289564A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA002289564A 1997-06-02 1998-06-01 Preparation of glycosylated tumor necrosis factor Abandoned CA2289564A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12097997A IL120979A0 (en) 1997-06-02 1997-06-02 Glycosylated TNF
IL120979 1997-06-02
PCT/IL1998/000254 WO1998055622A1 (en) 1997-06-02 1998-06-01 Preparation of glycosylated tumor necrosis factor

Publications (1)

Publication Number Publication Date
CA2289564A1 true CA2289564A1 (en) 1998-12-10

Family

ID=11070212

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002289564A Abandoned CA2289564A1 (en) 1997-06-02 1998-06-01 Preparation of glycosylated tumor necrosis factor

Country Status (6)

Country Link
EP (1) EP0985040A1 (ja)
JP (1) JP2002502257A (ja)
AU (1) AU746411B2 (ja)
CA (1) CA2289564A1 (ja)
IL (1) IL120979A0 (ja)
WO (1) WO1998055622A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
JP2008528006A (ja) * 2005-01-28 2008-07-31 アポロ ライフ サイエンシズ リミテッド 分子およびそのキメラ分子

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR851626B (ja) * 1984-07-05 1985-11-26 Genentech Inc
WO1988006625A2 (en) * 1987-02-26 1988-09-07 Cetus Corporation Arginine-depleted human tumor necrosis factor
US5378603A (en) * 1987-03-30 1995-01-03 Board Of Regents, The University Of Texas System Method and composition for identifying substances which activate transcription of the LDL receptor gene

Also Published As

Publication number Publication date
AU7546698A (en) 1998-12-21
AU746411B2 (en) 2002-05-02
WO1998055622A1 (en) 1998-12-10
EP0985040A1 (en) 2000-03-15
JP2002502257A (ja) 2002-01-22
IL120979A0 (en) 1997-11-20

Similar Documents

Publication Publication Date Title
US4650674A (en) Synergistic cytotoxic composition
RU2722374C1 (ru) Высокогликозилированный слитый белок на основе фактора свертывания крови человека viii, способ его получения и его применение
US7361738B2 (en) Megakaryocyte stimulating factors
AU599303B2 (en) Recombinant lymphotoxin
KR101761168B1 (ko) 재조합 ｆｓｈ 정제 방법
HU209153B (en) Method for producing and purifying proteines having effect of tumorous necrosis factor and another one for preparing pharmaceutical preparatives of synergetic effect containing said proteines and gamma-interferon
JP2002515247A (ja) Ｉｌ−２の選択的アゴニスト及びアンタゴニスト
JPH02442A (ja) エリトロポエチンを発現するヒトｃＤＮＡのクローニング方法
EA017733B1 (ru) СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
JPH08507201A (ja) リンホトキシン‐β、リンホトキシン‐β複合体、それらの薬学的な調製物および治療への使用
CA2223236C (en) Method for purifying thrombopoietin
CA1335360C (en) Recombinant natural killer cell activator
EP0290948A2 (en) Oncostatin M and novel compositions having anti-neoplastic activity
JP2580391B2 (ja) インタロイキン―４の精製法
AU746411B2 (en) Preparation of glycosylated tumor necrosis factor
US20060003407A1 (en) Methods for preparing highly active april ligand polypeptides
CN103044554B (zh) 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
WO1991009057A1 (en) Novel proteins with oncostatin m activity and process for their preparation
US6686455B1 (en) Tumor necrosis factor
RU2076151C1 (ru) Способ получения фактора некроза опухоли, человеческий фактор некроза опухоли
KR930010767B1 (ko) 종양 괴사 인자
JPH10212243A (ja) トロンボポエチン蛋白を含有する血小板止血血栓形成能回復促進用組成物
IE84574B1 (en) Fusion proteins with parts of immunoglobulins, their production and use

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued